Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
about
Fludarabine in the treatment of chronic lymphocytic leukemia: a reviewRichter transformation of CLL.The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.Detection of Hodgkin Transformation in a Case of Chronic Lymphocytic Leukemia by PET/CTCorrelation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.The spectrum of use of rituximab in chronic lymphocytic leukemiaAllogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when?Allogeneic transplantation for chronic lymphocytic leukemiaTransplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome.Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy.A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.Chronic lymphocytic leukemia: treatment options for patients with refractory disease.Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation FailureRelationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell LymphomaState-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.{(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo.Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemiaNovel targeted treatment strategies for refractory chronic lymphocytic leukaemia.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndromeIbrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.How we treat Richter syndrome.A systematic review on Richter syndrome: what is the published evidence?Salirasib in the treatment of pancreatic cancer.Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.Salvage therapy for relapsed chronic lymphocytic leukemia.Treatment of relapsed or refractory chronic lymphocytic leukemia.Cutaneous Richter syndrome: a better place to transform?Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.An update for Richter syndrome - new directions and developments.ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature.Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
P2860
Q24645173-64B647D2-8DF0-4FBA-ABE1-1A2BBC393B4EQ30249283-6CF49060-43AE-45E5-930B-DE60942CBB96Q31033615-23968D73-B72C-4F9D-AE87-0C7AD9B5A8B0Q33417548-848F047C-B19E-4A75-B8DA-468D4D4261BAQ33795848-37F76582-EB61-4D8A-AA31-19EF2B10F9D8Q34009015-2E49A754-D8D5-495E-BA2C-4452865A2FBEQ34269186-BD3D7DFC-5312-4C57-AE40-B917837DF6F7Q34510030-B498FEF5-9A43-42EA-A286-5BCA1F17CF1DQ34549285-559FC778-BD3F-4842-8090-C62B2BEE28F5Q34549313-F4728839-B99F-48EC-A0D5-DC01351C5E10Q34625543-08D2F9CF-F6C7-4CD7-890C-311BE37BE7E6Q35086905-6B4A124B-6A94-42D7-84F1-188A57B9B6D8Q35212176-86024DA6-2232-4188-A699-D0FC260B2024Q35296104-AE5478BC-7E96-43E2-B9AE-0475B8E9DB00Q35382716-B68F1F4E-DCC6-4789-89A3-2340B1611F8CQ35563832-2ABFF70F-FF8A-4201-983C-6887F75EDE00Q35714606-CFA569BD-831E-4DCD-AA8F-C47BEFE7315CQ35855599-B68A115B-ECC0-4CF7-AE5A-ADA8D2E96BE7Q35860550-AFB17A62-C774-4C00-B3EE-2DD4844D28F5Q36031384-CE649E9C-5A57-4C76-9589-1E01DC825D48Q36118111-B60DC02B-948B-4663-9400-294D08ADEBD8Q36612602-6CA8DECB-CBB9-4AE2-8DB2-288F60F432E0Q36826893-4993EC70-5762-4DFA-A7B7-323898DA359FQ36965455-45EDDEBF-9A28-4E12-B6FC-AA1AABF862CDQ37246532-38C95D40-D560-462A-85BB-1740ACDBEB1DQ37528067-BDE9D401-1999-468E-860F-5FBD8C26CE94Q37636962-23211B46-0641-4C1B-9F68-BD69DF3B7155Q37676244-37DBCF08-B789-49C1-970E-6834197D4A2DQ37763095-FA8AE3ED-20AA-4A42-9B00-0DBB56C3778AQ37764869-6EB71AE6-D031-4F0D-AE57-F814FD5B5689Q37865547-A1EF565F-DBEC-47F9-BAED-B3E2DDA8D642Q37964916-1AAA50F6-7216-4777-88C4-7844D41AADF1Q38220731-112C743E-86D9-4752-A293-492337E05094Q38221083-61E53536-84ED-459A-B207-ADF996F3CE2CQ38263924-A8D82270-60BC-4E65-85DE-19E10B037A59Q38691261-764A1768-61A7-4392-A434-81B81998CFD1Q38891225-7AF9A0BB-F9F7-443E-A191-11BCC180C1DEQ38896306-AE5F0347-36AB-46B7-8F78-19DF94C3867FQ39025300-36E7B574-BC01-438E-BAAC-8D9689ABCD7EQ39380445-985B5652-D97E-456D-A7CF-633F00A7C0D3
P2860
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Phase I-II study of oxaliplati ...... chronic lymphocytic leukemia.
@en
Phase I-II study of oxaliplati ...... chronic lymphocytic leukemia.
@nl
type
label
Phase I-II study of oxaliplati ...... chronic lymphocytic leukemia.
@en
Phase I-II study of oxaliplati ...... chronic lymphocytic leukemia.
@nl
prefLabel
Phase I-II study of oxaliplati ...... chronic lymphocytic leukemia.
@en
Phase I-II study of oxaliplati ...... chronic lymphocytic leukemia.
@nl
P2093
P50
P356
P1476
Phase I-II study of oxaliplati ...... chronic lymphocytic leukemia.
@en
P2093
Albert Fiorentino
Farhad Ravandi-Kashani
Jennifer R Brown
Thomas J Kipps
P304
P356
10.1200/JCO.2007.11.8513
P407
P50
P577
2008-01-01T00:00:00Z